Compare Adaptive Biotechnologies Corp (ADPT) vs Tapestry, Inc. (TPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Tapestry, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Tapestry, Inc. trades at $140.14 (market cap $29.40B). The key difference: Tapestry, Inc. is far larger — about 8.8× Adaptive Biotechnologies Corp's market cap, and Tapestry, Inc. pays a 1.1% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TPR | |
|---|---|---|
Market Cap | $3.33B | $29.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $160.49 |
52-Week Low | $10.24 | $92.20 |
Enterprise Value | $3.19B | $32.25B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
TPR trades at $146.3, up 1.45% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. The company maintains high profitability margins, including a 76.18% gross margin and 55.74% ROE, though net income margin declined to 8.44% in 2025. Positive news highlights digital growth and Gen Z engagement, with a consensus price target of $184.14 implying significant upside.
Outlook is positive given earnings momentum and analyst optimism, but risks include high debt levels, volatile cash flows, and competitive pressures in the luxury retail sector. The stock's elevated P/E of 44.36 requires sustained growth to justify valuation, while institutional ownership trends and insider activity should be monitored for confirmation of bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
